Dormeshkin Dmitri, PhD | Immunofusion; Alex Migas, PhD; Mikalai Katsin, MD
Competition Sponsor: EIT Health
Awardee Year: 2025
Immunofusion is a privately held biotech company committed to developing next-generation cell therapies that overcome the limitations of current CAR T technologies. While CAR T-cell therapies have transformed cancer and autoimmune disease treatment, they remain constrained by low durable response rates, toxicity, and manufacturing bottlenecks.